Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 11α-hydroxyprogesterone is a potent inhibitor of 11βHSD2 in vitro and may serve as a precursor to unique C11α-hydroxy steroids in prostate cancer tissue.

This case report suggests that Roux-en-Y gastric bypass may improve symptoms of non-classic adrenal hyperplasia related to 11-hydroxylase deficiency by reducing insulin resistance.

This case report suggests that a supplement containing biotin, beta carotene, vitamin C, zinc, and copper may improve insulin resistance markers and hair loss in a patient with non-classic 11-hydroxylase deficiency.

In this case study, drospirenone use masked the diagnosis of a rare form of congenital adrenal hyperplasia, suggesting a possible delay in detecting underlying endocrinopathies.

This study determined that nonclassical congenital adrenal hyperplasia has a 2.2% prevalence among hyperandrogenic women in Spain, with basal serum 17-hydroxyprogesterone showing excellent diagnostic performance.

This study found that serum steroid profiling, particularly 11-deoxycortisol, can effectively differentiate between ACC and ACA, while considering sex differences and functional status for other steroids is important.

Skin hormone levels change significantly after menopause.

This study found that measuring specific steroid hormone levels can aid in diagnosing P450 oxidoreductase deficiency, a subtype of congenital adrenal hyperplasia, by distinguishing affected patients from healthy individuals.

In this case study, a woman with non-classical adrenal hyperplasia experienced reduced levels of specific adrenal steroids and less scalp hair loss after self-treating with Ashwagandha for six months.

This report describes an elderly woman whose nonclassic 11-hydroxylase deficiency, presenting as acne and male pattern alopecia, may have been ameliorated by Ashwagandha root in a dose-related manner.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This review discusses the challenges in diagnosing different causes of adult androgen excess and outlines current screening and management strategies but reports no new findings.

This study found that 11-oxygenated androgens were higher in women with PCOS compared to those with idiopathic hirsutism, with no difference from controls, and higher Bisphenol A levels in obese women with PCOS may worsen metabolic issues.

This study describes a case of a 35-year-old woman who developed symptoms of hyperandrogenism and disrupted steroidogenesis due to chronic use of electronic cigarettes containing compounds similar to etomidate, despite no genetic mutation indicating 11β-hydroxylase deficiency.

In this study, adolescents with depressive symptoms were found to have higher urinary excretion rates of certain steroid metabolites, including corticosterone and adrenal hormones, and a specific metabolite ratio was identified as a potential biomarker for distinguishing these patients from healthy controls.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

In this study, PCOS was the most common cause of hirsutism among Turkish women, but about 17% had idiopathic hyperandrogenemia with no clear cause identified.

This review discusses alternative androgen pathways, including the "backdoor" pathway and pathways to 11-oxygenated steroids, and reports no new clinical results; the authors aim to clarify these concepts for better patient treatment.

This study used a novel extraction method to detect and measure mineralocorticoids and glucocorticoids in hair follicles, concluding these steroids may serve as effective biomarkers for diagnosing conditions related to steroid excess or deficiency, such as Cushing’s syndrome and congenital adrenal hyperplasia.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

This study suggests that daughters of women with PCOS may have altered androgen metabolism in early childhood, with increased 5α-reductase activity potentially contributing to PCOS development.

This study found trilostane to be an effective and generally safe treatment for improving symptoms in dogs with pituitary-dependent hyperadrenocorticism.

This review discusses various treatment options for non-classic congenital adrenal hyperplasia due to 21α-hydroxylase and 11β-hydroxylase deficiencies without providing new clinical results.

This article discusses the ongoing care needs for individuals with 21-hydroxylase deficiency due to mutations in the CYP21A2 gene but does not present new clinical findings.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

This article discusses the challenges in diagnosing non-classical congenital adrenal hyperplasia and emphasizes personalized treatment approaches, reporting no new clinical results.

This study found that plasma protein binding significantly contributes to the shifts in glucocorticosteroid concentration ratios among blood, saliva, and hair, challenging prior assumptions about enzyme inactivation as the main factor.

This study concluded that neither basal nor ACTH-stimulated 17-OHP concentrations effectively indicate carrier status for 21-hydroxylase deficiency among Slovenian hyperandrogenic women, recommending molecular analysis of the CYP21 gene for reliable screening.

This study found that metyrapone and etomidate provide dose-dependent anticonvulsant effects against seizures, with delayed effectiveness linked to increased neurosteroid levels.